These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 10487693)

  • 1. Loss of heterozygosity of the long arm of chromosome 7 in follicular and anaplastic thyroid cancer, but not in papillary thyroid cancer.
    Trovato M; Fraggetta F; Villari D; Batolo D; Mackey K; Trimarchi F; Benvenga S
    J Clin Endocrinol Metab; 1999 Sep; 84(9):3235-40. PubMed ID: 10487693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential loss of heterozygosity at 7q31.2 in follicular and papillary thyroid tumors.
    Zhang JS; Nelson M; McIver B; Hay ID; Goellner JR; Grant CS; Eberhardt NL; Smith DI
    Oncogene; 1998 Aug; 17(6):789-93. PubMed ID: 9715281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of heterozygosity in 73 human thyroid tumors.
    Wozniak A; Wiench M; Olejniczak A; Wloch J; Lachinski A; Lange D; Olczyk T; Jarzab B; Limon J
    Neuro Endocrinol Lett; 2005 Oct; 26(5):521-5. PubMed ID: 16264407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of heterozygosity in follicular and papillary thyroid carcinomas.
    Rodrigues-Serpa A; Catarino A; Soares J
    Cancer Genet Cytogenet; 2003 Feb; 141(1):26-31. PubMed ID: 12581895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HGF/C-MET system pathways in benign and malignant histotypes of thyroid nodules: an immunohistochemical characterization.
    Ruggeri RM; Vitarelli E; Barresi G; Trimarchi F; Benvenga S; Trovato M
    Histol Histopathol; 2012 Jan; 27(1):113-21. PubMed ID: 22127603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High resolution loss of heterozygosity mapping of 17p13 in thyroid cancer: Hurthle cell carcinomas exhibit a small 411-kilobase common region of allelic imbalance, probably containing a novel tumor suppressor gene.
    Farrand K; Delahunt B; Wang XL; McIver B; Hay ID; Goellner JR; Eberhardt NL; Grebe SK
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4715-21. PubMed ID: 12364463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Loss of heterozygosity on chromosome 3p in thyroid tumors].
    Hu MJ; Xu HD; Zhou R; Li XF; Zhang HY
    Zhonghua Bing Li Xue Za Zhi; 2008 May; 37(5):305-8. PubMed ID: 18956647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytogenetic and molecular genetic studies of follicular and papillary thyroid cancers.
    Herrmann MA; Hay ID; Bartelt DH; Ritland SR; Dahl RJ; Grant CS; Jenkins RB
    J Clin Invest; 1991 Nov; 88(5):1596-604. PubMed ID: 1939648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies of allelic loss in thyroid tumors reveal major differences in chromosomal instability between papillary and follicular carcinomas.
    Ward LS; Brenta G; Medvedovic M; Fagin JA
    J Clin Endocrinol Metab; 1998 Feb; 83(2):525-30. PubMed ID: 9467569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of heterozygosity on chromosome 16p and 18q in anaplastic thyroid carcinoma.
    Kadota M; Tamaki Y; Sekimoto M; Fujiwara Y; Aritake N; Hasegawa S; Kobayashi T; Ikeda T; Horii A; Monden M
    Oncol Rep; 2003; 10(1):35-8. PubMed ID: 12469141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequent loss of heterozygosity on chromosomes 3p and 17p without VHL or p53 mutations suggests involvement of unidentified tumor suppressor genes in follicular thyroid carcinoma.
    Grebe SK; McIver B; Hay ID; Wu PS; Maciel LM; Drabkin HA; Goellner JR; Grant CS; Jenkins RB; Eberhardt NL
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3684-91. PubMed ID: 9360526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathological Significance of Overall Frequency of Allelic Loss (OFAL) in Lesions Derived from Thyroid Follicular Cell.
    Migdalska-Sęk M; Czarnecka KH; Kusiński M; Pastuszak-Lewandoska D; Nawrot E; Kuzdak K; Brzeziańska-Lasota E
    Mol Diagn Ther; 2019 Jun; 23(3):369-382. PubMed ID: 30747408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frizzled-1 is down-regulated in follicular thyroid tumours and modulates growth and invasiveness.
    Ulivieri A; Lavra L; Dominici R; Giacomelli L; Brunetti E; Sciacca L; Trovato M; Barresi G; Foukakis T; Jia-Jing L; Larsson C; Bartolazzi A; Sciacchitano S
    J Pathol; 2008 May; 215(1):87-96. PubMed ID: 18306168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of the hepatocyte growth factor and c-met in normal thyroid, non-neoplastic, and neoplastic nodules.
    Trovato M; Villari D; Bartolone L; Spinella S; Simone A; Violi MA; Trimarchi F; Batolo D; Benvenga S
    Thyroid; 1998 Feb; 8(2):125-31. PubMed ID: 9510120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anaplastic carcinoma of the thyroid arising more often from follicular carcinoma than papillary carcinoma.
    Wang HM; Huang YW; Huang JS; Wang CH; Kok VC; Hung CM; Chen HM; Tzen CY
    Ann Surg Oncol; 2007 Oct; 14(10):3011-8. PubMed ID: 17638058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Caveolin-1 and caveolin-2,together with three bone morphogenetic protein-related genes, may encode novel tumor suppressors down-regulated in sporadic follicular thyroid carcinogenesis.
    Aldred MA; Ginn-Pease ME; Morrison CD; Popkie AP; Gimm O; Hoang-Vu C; Krause U; Dralle H; Jhiang SM; Plass C; Eng C
    Cancer Res; 2003 Jun; 63(11):2864-71. PubMed ID: 12782592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anaplastic thyroid cancer: cytogenetic patterns by comparative genomic hybridization.
    Miura D; Wada N; Chin K; Magrane GG; Wong M; Duh QY; Clark OH
    Thyroid; 2003 Mar; 13(3):283-90. PubMed ID: 12729478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinctive expression of STAT3 in papillary thyroid carcinomas and a subset of follicular adenomas.
    Trovato M; Grosso M; Vitarelli E; Ruggeri RM; Alesci S; Trimarchi F; Barresi G; Benvenga S
    Histol Histopathol; 2003 Apr; 18(2):393-9. PubMed ID: 12647789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-expression of interleukin-6 (IL-6) and interleukin-6 receptor (IL-6R) in thyroid nodules is associated with co-expression of CD30 ligand/CD30 receptor.
    Ruggeri RM; Villari D; Simone A; Scarfi R; Attard M; Orlandi F; Barresi G; Trimarchi F; Trovato M; Benvenga S
    J Endocrinol Invest; 2002 Dec; 25(11):959-66. PubMed ID: 12553555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can the microRNA signature distinguish between thyroid tumors of uncertain malignant potential and other well-differentiated tumors of the thyroid gland?
    Lassalle S; Hofman V; Ilie M; Bonnetaud C; Puisségur MP; Brest P; Loubatier C; Guevara N; Bordone O; Cardinaud B; Lebrigand K; Rios G; Santini J; Franc B; Mari B; Al Ghuzlan A; Vielh P; Barbry P; Hofman P
    Endocr Relat Cancer; 2011 Oct; 18(5):579-94. PubMed ID: 21778212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.